Price$4.00-0.12 (-2.80%)
01:30 PM07:45 PM
News · 26 weeks62-20%
2026-04-192026-10-11
Mix4790d
- Other23(49%)
- SEC Filings20(43%)
- Earnings2(4%)
- Leadership2(4%)
Latest news
25 items- SECAmendment: SEC Form SC14D9F/A filed by Aurora Cannabis Inc.SC14D9F/A - AURORA CANNABIS INC (0001683541) (Subject)
- SECSEC Form 6-K filed by Aurora Cannabis Inc.6-K - AURORA CANNABIS INC (0001683541) (Filer)
- PRAurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future UpsideNASDAQ | TSX: ACBRevised Hostile Bid continues to significantly undervalue Aurora; fails to address concerns previously raised by the Board. Aurora's Special Committee is actively exploring strategic alternatives to maximize value for Aurora shareholders. Shareholders are advised to REJECT the revised Hostile Bid and TAKE NO ACTION at this time before other strategic alternatives may emerge. Questions about the Hostile Bid or would like to stay informed? Contact Kingsdale Advisors toll-free at 1-800-749-9052 within North America, call or text 416-623-4172 or email contactus@kingsdaleadvisors.com.EDMONTON, AB, Oct. 14, 2026 /CNW/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX:ACB) (
- SECSEC Form 6-K filed by Aurora Cannabis Inc.6-K - AURORA CANNABIS INC (0001683541) (Filer)
- PRAurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower OutputNASDAQ | TSX: ACBMulti-million-dollar investment results in increased domestic production capacity in Germany, more than doubling expected annual flower output.Enhanced facility adopts Aurora's proven cultivation practices and proprietary genetics to support consistent, high-quality production.Expanded EU-GMP manufacturing capacity reinforces Aurora's ability to deliver compliant, high-quality products across European markets as demand increases. EDMONTON, AB, Oct. 8, 2026 /CNW/ -- Aurora Cannabis Inc. (TSX: ACB) (NASDAQ:ACB), the leading Canadian-based global medical cannabis company, today announced the completion of a major expansion of its facility in Leuna, Germany. The expansion projec
- SECAmendment: SEC Form SC14D9F/A filed by Aurora Cannabis Inc.SC14D9F/A - AURORA CANNABIS INC (0001683541) (Subject)
- PRAurora Urges Shareholders to Take No Action to Revised Hostile Bid by Curaleaf as Formal Review UnderwayAurora's Special Committee will commence a thorough and independent review of the revised Hostile Bid and the Board will provide a formal recommendation to shareholders once the review is complete. Shareholders are advised to TAKE NO ACTION pending a formal recommendation. Aurora shareholders will have until at least December 4, 2026, to consider their options.Questions about the Hostile Bid or would like to stay informed? Please contact Kingsdale Advisors toll-free at 1-800-749-9052 within North America, call or text 416-623-4172 or at contactus@kingsdaleadvisors.com.EDMONTON, AB, Oct. 6, 2026 /CNW/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX:ACB) (NASDAQ:ACB), the Canadian-ba
- SECAmendment: SEC Form SC14D9F/A filed by Aurora Cannabis Inc.SC14D9F/A - AURORA CANNABIS INC (0001683541) (Subject)
- PRAurora Maintains Shareholder Recommendation to Take No Action at this Time as Curaleaf Has Yet to File Their Revised Hostile BidNASDAQ | TSX: ACBCuraleaf has yet to file a Notice of Variation and Change to revise its offer. Once filed, the Special Committee will complete a thorough and comprehensive review prior to issuing a formal recommendation to shareholdersAurora's application to the Alberta Securities Commission delivered results for shareholders: Curaleaf's latest update indicates that Aurora shareholders will be provided with pro forma financials and a bid timeline that complies with securities lawsQuestions about the Hostile Bid or would like to stay informed? Please contact Kingsdale Advisors toll-free at 1-800-749-9052 within North America, call or text 416-623-4172 or at contactus@kingsdaleadvisors.com.ED
- SECAmendment: SEC Form SC14D9F/A filed by Aurora Cannabis Inc.SC14D9F/A - AURORA CANNABIS INC (0001683541) (Subject)
- SECSEC Form 6-K filed by Aurora Cannabis Inc.6-K - AURORA CANNABIS INC (0001683541) (Filer)
- PRAurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid DisclosureNASDAQ | TSX: ACBAurora has filed an application with the Alberta Securities Commission for an order requiring Curaleaf to comply with securities laws.Aurora intends to demonstrate that Curaleaf's Circular has not satisfied several regulatory requirements, impacting Aurora Shareholders, including providing pro-forma financials and keeping the hostile bid open for the minimum period. Curaleaf has refused to address deficiencies identified by Aurora in its hostile bid Circular that are believed to limit Aurora shareholders' access to disclosures required by securities laws before responding to its hostile bid.Aurora is
- SECSEC Form 6-K filed by Aurora Cannabis Inc.6-K - AURORA CANNABIS INC (0001683541) (Filer)
- PRAurora Cannabis Provides Business Update; Accretive Acquisition of Safari Flower Company and Leading European Performance Expected to Fuel International Growth in the Fiscal Second Quarter 2027 and BeyondNASDAQ| TSX: ACBRe-affirms FY27 Q2 guidance for sequential growth in quarterly net revenue and adjusted EBITDA1Following the receipt of EU-GMP certification in July, Safari Flower Company is expected to contribute incremental net revenue and adjusted EBITDA1 Continued strong performance in Germany and Poland, contributing to profitable international growth expectations and leadership positions in the two largest EU markets, including #1 market share by revenue in Poland UK market expansion underway, with recently announced acquisition of Internode Pharma and HAP Pharma Limited expected to support further market share growthEDMONTON, AB, Sept. 16, 2026 /CNW/ -- Aurora Cannabis Inc. ("Aurora"
- SECAmendment: SEC Form SC14D9F/A filed by Aurora Cannabis Inc.SC14D9F/A - AURORA CANNABIS INC (0001683541) (Subject)
- SECSEC Form 6-K filed by Aurora Cannabis Inc.6-K - AURORA CANNABIS INC (0001683541) (Filer)
- PRAurora Cannabis Refutes Curaleaf's Latest Attempt To Distract Shareholders From The FactsNASDAQ | TSX: ACBCuraleaf's announcement is a desperate effort to shift attention away from the fundamental issue facing shareholders: its inadequate hostile bid undervalues Aurora.Curaleaf's attempt to fabricate issues ignores the reality of its own balance sheet: more than $1 billion of debt1, including $500 million carrying an 11.5% interest rate, exposing shareholders to significant financial and dilution risks.Curaleaf's criticism ignores four key facts: Aurora's ATM was publicly disclosed months before the hostile bid, was designed to support accretive acquisitions in Canada and the UK, has been inactive for several weeks and, prior to February 2026, had not been utilized by Aurora for
- SECSEC Form 6-K filed by Aurora Cannabis Inc.6-K - AURORA CANNABIS INC (0001683541) (Filer)
- PRAurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis BusinessEDMONTON, AB, Sept. 9, 2026 /CNW/ -- Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, announces Faris El Refaie, a biopharmaceutical leader with 25 years of experience, will join the company as Executive Vice President, Global Commercial, effective September 28, 2026. In this newly created role, Faris will oversee Aurora's global commercial function, with responsibility for furthering the company's medical cannabis market strategy, aligning its global portfolio, growing customer engagement and accelerating commercial capabilities across Canada, Europe, Australia, New Zeala
- PRCuraleaf Responds to Aurora Circular; Reaffirms Offer as the Best Path to Value Creation for ShareholdersHighlightsCuraleaf Offers a 45% Premium and Meaningful Future Upside: Aurora shareholders can realize immediate value alongside the opportunity to participate in the upside of a substantially larger, more diversified cannabis platform.Aurora Promotes a "Debt-Free" Balance Sheet While Overlooking Years of Shareholder Dilution to Fund It: Since September 2020, Aurora has raised $398 million in capital at the expense of shareholders through equity issuances, resulting in massive shareholder dilution. Additional dilution continues through its existing "At the Market" (ATM) program.Aurora's Board Doesn't Believe Its Own Valuation Argument: Within the last two quarters, Aurora's Board sold shares
- SECSEC Form 6-K filed by Aurora Cannabis Inc.6-K - AURORA CANNABIS INC (0001683541) (Filer)
- SECSEC Form F-X filed by Aurora Cannabis Inc.F-X - AURORA CANNABIS INC (0001683541) (Subject)
- SECSEC Form SC14D9F filed by Aurora Cannabis Inc.SC14D9F - AURORA CANNABIS INC (0001683541) (Subject)
- PRAurora Cannabis Urges Shareholders to REJECT Curaleaf's Hostile Bid, Warning that it is Inadequate, Undervalues Aurora and Puts Shareholder Value and Future Upside at RiskNASDAQ | TSX: ACBCuraleaf's hostile and opportunistic bid significantly undervalues Aurora, and aims to capture Aurora's assets at a discountAurora is debt free and holds $149 million in cash1, Curaleaf carries over $1 billion in debt2, Aurora shareholders' own cash should not be used to help fix Curaleaf's balance sheetThe hostile bid exposes Aurora shareholders to significant risks not fairly disclosed and could meaningfully weaken shareholder rightsAurora's transformation into a global, high-margin medical cannabis leader is delivering results, and the Board believes significant value creation lies aheadAurora Files Directors' Circular Unanimously Recommending Shareholders REJECT Curaleaf
- PRCuraleaf Responds to Aurora Cannabis' Latest Attempt to Deflect From Shareholder Value CreationAurora's selective statistics and misleading characterization of engagement do not obscure years of underperformance and lost shareholder valueCuraleaf reiterates its willingness to meet anytime to discuss a deal in the best interests of shareholdersSTAMFORD, Conn., Aug. 24, 2026 /CNW/ -- Curaleaf Holdings, Inc. (TSX:CURA) (OTCQX:CURLF) ("Curaleaf"), a leading international provider of consumer and medical cannabis products, today responded to Aurora Cannabis Inc.'s (TSX:ACB) (NASDAQ: ACB) ("Aurora") latest public statements regarding Curaleaf's offer for Aurora: "Aurora's hollow protests and completely misleading statistics ch
ACB FAQ
6 questionsWhat does Aurora Cannabis Inc. do?
Aurora Cannabis Inc. produces and distributes medical cannabis products worldwide. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, including facility engineering and design, cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories, including valves, screens...Where does ACB stock trade?
Aurora Cannabis Inc. (ACB) is listed on NYSE.What sector and industry is ACB in?
Aurora Cannabis Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.What are analysts saying about ACB?
Aurora Cannabis Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-01-27. Recent price targets range from $960.00 to $1075.00.What companies are similar to ACB?
Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), DFTX (Definium Therapeutics Inc.), RGC (Regencell Bioscience Holdings Limited). Compare ACB side-by-side with any of them on Quantisnow.How can I track ACB on Quantisnow?
Quantisnow aggregates Aurora Cannabis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACB to receive live email and push alerts on every new disclosure.